MedTrace Logo

Liver Cancer Disparities in American Indian and Alaska Native Persons

NCT05304234 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-06-04

No results posted yet for this study

Summary

We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.

Conditions

Interventions

DIAGNOSTIC_TEST

Ultrasound or abbreviated MRI

Abdominal ultrasound or abbreviated MRI

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Cherokee Nation Health Services

    collaborator UNKNOWN

  • Alaska Native Tribal Health Consortium

    collaborator OTHER

  • University of Washington

    lead OTHER

Principal Investigators

  • George Ioannou, MD, MS · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2025-09-01
Completion
2026-09-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05304234 on ClinicalTrials.gov